恩格列净和芬尼酮联合治疗CKD和T2DM患者优于单药治疗

IF 28.6 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Nephrology Pub Date : 2025-06-27 DOI:10.1038/s41581-025-00986-7

Ellen F. Carney

{"title":"恩格列净和芬尼酮联合治疗CKD和T2DM患者优于单药治疗","authors":"Ellen F. Carney","doi":"10.1038/s41581-025-00986-7","DOIUrl":null,"url":null,"abstract":"New data from the CONFIDENCE trial show that combination therapy with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, and the nonsteroidal mineralocorticoid receptor antagonist, finerenone, resulted in a significantly greater reduction in albuminuria than either treatment alone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). These results were presented at the 62nd European Renal Association Congress in Vienna.Rajiv Agarwal and colleagues randomly assigned 818 patients with CKD and T2DM to combination therapy or monotherapy with empagliflozin or finerenone. All participants also received the maximum tolerated labelled dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was change in urinary albumin to creatinine ratio (UACR) from baseline to day 180.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"46 1","pages":""},"PeriodicalIF":28.6000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Superior efficacy of empagliflozin and finerenone combination therapy versus monotherapy in patients with CKD and T2DM\",\"authors\":\"Ellen F. Carney\",\"doi\":\"10.1038/s41581-025-00986-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New data from the CONFIDENCE trial show that combination therapy with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, and the nonsteroidal mineralocorticoid receptor antagonist, finerenone, resulted in a significantly greater reduction in albuminuria than either treatment alone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). These results were presented at the 62nd European Renal Association Congress in Vienna.Rajiv Agarwal and colleagues randomly assigned 818 patients with CKD and T2DM to combination therapy or monotherapy with empagliflozin or finerenone. All participants also received the maximum tolerated labelled dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was change in urinary albumin to creatinine ratio (UACR) from baseline to day 180.\",\"PeriodicalId\":19059,\"journal\":{\"name\":\"Nature Reviews Nephrology\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":28.6000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41581-025-00986-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41581-025-00986-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

来自CONFIDENCE试验的新数据显示，在慢性肾脏疾病（CKD）和2型糖尿病（T2DM）患者中，联合使用钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂恩格列净和非甾体矿物皮质激素受体拮抗剂芬尼酮，可显著降低蛋白尿。这些结果在维也纳举行的第62届欧洲肾脏协会大会上公布。Rajiv Agarwal及其同事将818名CKD和T2DM患者随机分配到联合治疗或单药恩格列净或芬尼酮组。所有参与者还接受了最大耐受标记剂量的血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。主要终点是尿白蛋白与肌酐比值（UACR）从基线到180天的变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Superior efficacy of empagliflozin and finerenone combination therapy versus monotherapy in patients with CKD and T2DM

New data from the CONFIDENCE trial show that combination therapy with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, and the nonsteroidal mineralocorticoid receptor antagonist, finerenone, resulted in a significantly greater reduction in albuminuria than either treatment alone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). These results were presented at the 62nd European Renal Association Congress in Vienna.

Rajiv Agarwal and colleagues randomly assigned 818 patients with CKD and T2DM to combination therapy or monotherapy with empagliflozin or finerenone. All participants also received the maximum tolerated labelled dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was change in urinary albumin to creatinine ratio (UACR) from baseline to day 180.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Nephrology 医学-泌尿学与肾脏学

CiteScore

39.00

自引率

1.20%

发文量

127

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Nephrology aims to be the premier source of reviews and commentaries for the scientific communities it serves. It strives to publish authoritative, accessible articles. Articles are enhanced with clearly understandable figures, tables, and other display items. Nature Reviews Nephrology publishes Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements. The content is relevant to nephrologists and basic science researchers. The broad scope of the journal ensures that the work reaches the widest possible audience.